Evidence map›Paper›PMID 30725205›Full record

Trial reportCancer immunology, immunotherapy : CII2019

A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanoma.

Lorena P Suarez-Kelly, Kala M Levine, Thomas E Olencki, Sara E Martin Del Campo, Elizabeth A Streacker, Taylor R Brooks, Volodymyr I Karpa, Joseph Markowitz, Anissa K Bingman, Susan M Geyer and 2 more

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer immunology, immunotherapy : CII, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Impact of Interferon-alpha1b (IFN-α1b) on Antitumor Immune Response: An Interpretation of the Promising Therapeutic Effect of IFN-alpha1b on Melanoma.Medical science monitor : international medical journal of experimental and clinical research · 2020
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Lorena P Suarez-KellyComprehensive Cancer Center, The Ohio State University, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, N924 Doan Hall 410 W. 10th Ave, Columbus, OH, 43210-1228, USA.
Kala M LevineComprehensive Cancer Center, The Ohio State University, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, N924 Doan Hall 410 W. 10th Ave, Columbus, OH, 43210-1228, USA.
Thomas E OlenckiMedical Oncology, Department of Internal Medicine, The Ohio State University, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH, USA.
Sara E Martin Del CampoDepartment of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Elizabeth A StreackerPromedica Toledo Hospital, Toledo, OH, USA.
Taylor R BrooksDivision of Rheumatology and Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Volodymyr I KarpaComprehensive Cancer Center, The Ohio State University, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, N924 Doan Hall 410 W. 10th Ave, Columbus, OH, 43210-1228, USA.
Joseph MarkowitzComprehensive Cancer Center, The Ohio State University, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, N924 Doan Hall 410 W. 10th Ave, Columbus, OH, 43210-1228, USA.
Anissa K BingmanDepartment of Biomedical Informatics, The Ohio State University College of Medicine, Columbus, OH, USA.
Susan M GeyerDepartment of Biomedical Informatics, The Ohio State University College of Medicine, Columbus, OH, USA.
Kari L KendraMedical Oncology, Department of Internal Medicine, The Ohio State University, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH, USA.
William E CarsonComprehensive Cancer Center, The Ohio State University, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, N924 Doan Hall 410 W. 10th Ave, Columbus, OH, 43210-1228, USA. william.carson@osumc.edu.ORCID http://orcid.org/0000-0001-8099-4743

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3M
TWO SIGNAL REQUIREMENT FOR NATURAL KILLER IMMUNITYP01CA095426 · NCI · OHIO STATE UNIVERSITY · PI TRIDANDAPANI, SUSHEELA · 2002 to 2016
$29.6M
UM1 Supplement for Early Therapeutic Trials with Phase 2 IntentUM1CA186712 · NCI · OHIO STATE UNIVERSITY · PI SUSANNE M ARNOLD, WILLIAM E. CARSON · 2014 to 2026
$19.3M
PHASE I TRIALS OF ANTICANCER AGENTSU01CA076576 · NCI · OHIO STATE UNIVERSITY · PI GREVER, MICHAEL R · 1998 to 2013
$9.1M
Tumor ImmunologyT32CA090223 · NCI · OHIO STATE UNIVERSITY · PI CARSON, WILLIAM E. · 2002 to 2023
$4.1M
A Program of Immune-Based Treatments for CancerK24CA093670 · NCI · OHIO STATE UNIVERSITY · PI CARSON, WILLIAM E. · 2002 to 2012
$1.7M
NCI NIH HHS P30 CA016058NCI NIH HHS U01 CA076576NCI NIH HHS UM1 CA186712NIH HHS K24 CA093670NIH HHS P01 CA095426NIH HHS P30 CA16058NIH HHS T32 5T32CA090223-12NIH HHS T32 CA090223NIH HHS U01 CA76576
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Adjuvants, PharmaceuticAdultAgedCells, CulturedDrug Dosage CalculationsFemaleHumansInterferon-alphaInterferon alpha-2Interferon Regulatory FactorsJanus KinasesLeukocytes, MononuclearMaleMelanomaMiddle AgedPilot ProjectsAdjuvants, PharmaceuticInterferon-alphaInterferon alpha-2Interferon-alpha2bInterferon Regulatory FactorsJanus KinasesSTAT Transcription Factors

Identifiers

PMID30725205
PMCPMC6447692

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.